We use a Google Analytics cookie to gather anonymous information about how our site is used.
If you continue using our site we'll assume that you are happy for the use of this cookie to continue.
Speak with one of our advisors: 0800 085 6663 or
 

Exercise could be new treatment for prostate cancer

A newly launched Cancer Research UK study could be the first step towards exercise training being introduced as a new NHS treatment for prostate cancer.

The PANTERA study, led by Sheffield Hallam University, will focus on 50 men who have the disease, but whose cancer has not spread. This trial – believed to be the first of its kind in the world – would aim to test whether regular exercise can help keep prostate cancer from spreading to other parts of the body and could be a viable NHS treatment.

 

Half of the men in the study will carry out two-and-a-half hours of aerobic exercise every week for 12 months – initially with the support of a qualified trainer and then with free access to local gyms. The other half will be given information about the benefits of exercise for cancer patients but will have no supervised sessions.

In the UK, prostate cancer is the most common cancer in men with around 43,400 new cases diagnosed each year and around 10,800 deaths. Many types of prostate cancer grow extremely slowly and are not likely to spread, while others are more aggressive.

Prostate cancer that has not spread is sometimes treated with surgery or radiotherapy. But this can have side effects, and many men opt for active surveillance instead, which involves monitoring the disease. All the men in the PANTERA study are and will remain on active surveillance – and they will also be closely monitored as part of the study itself.

If the participants can successfully keep up their exercise regime for 12 months, the study is expected to lead to a full-scale trial to look at the potential benefits of combining active surveillance and exercise for some prostate cancer patients.

Study leader Dr Liam Bourke, principal research fellow at Sheffield Hallam University, said: “Evidence suggests that men who are physically active after a prostate cancer diagnosis have better cancer survival than men who aren’t active. It’s not clear yet how this works, but it might be that exercise affects the way some genes regulate cancer cell growth and DNA repair.

“The clinical academic team in Sheffield have been working hard for eight years to develop the intervention that is being tested in this exciting study. It builds on what we already know and is the first step towards finding out whether exercise could be an effective and practical NHS treatment for localised prostate cancer. If we show it works and is feasible, it could be a real leap forward and good news for cancer patients.”

PSA is produced by both normal and cancerous prostate cells, and a high PSA level in the blood can be a sign of cancer. Study researchers will check what effect regular exercise has on the body, including on PSA levels, and will also gather information about how well the study runs, to prepare for a full-scale trial.

Vincent Gnanapragasam, consultant urological surgeon at the University of Cambridge and Addenbrookes Hospital, and Clinical Adviser to Check4Cancer, comments:“Exercise is clearly of benefit to us all, and is one of the key lifestyle factors that can help reduce our risk of a range of common cancers. The possibility that it can also help to hold back the disease is a very exciting one – not least because it restores some sense of control to the patient at a time when those with the disease can feel powerless and dispirited. Any new treatment is to be warmly welcomed – especially one that is relatively low cost and easy to administer, as this is – but the ability to take direct action against the disease also provides distinct psychological advantages. This is exactly why one of Check4Cancer’s aims is to give control of ones health back to the individual, wherever it is possible to do so.”

© 2019 Check4Cancer, 1 The Mill, Copley Hill Business Park, Cambridge Road, Cambridge CB22 3GN
Registered in England and Wales. Company registration number 08866941